Take­da and Zin­fan­del write off yet an­oth­er Alzheimer’s PhI­II af­ter Ac­tos fails a key in­ter­im test

Hours af­ter Eli Lil­ly spelled out ex­act­ly how bad its last batch of Phase III da­ta for solanezum­ab was, Take­da stepped up to say its big shot at prov­ing that their di­a­betes drug Ac­tos could al­so de­lay symp­toms of Alzheimer’s was a com­plete flop.

De­scribed as the biggest Phase III in Alzheimer’s to date when it was ful­ly en­rolled in ear­ly 2016, the TO­MOR­ROW study re­cruit­ed more than 3,500 pa­tients at 50 sites to test a low dose of Ac­tos, us­ing a ge­net­ic-based bio­mark­er risk as­sign­ment al­go­rithm from the small US biotech Zin­fan­del Phar­ma­ceu­ti­cals, a Duke spin­out, to iden­ti­fy the best sub­jects.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER